These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

390 related articles for article (PubMed ID: 25435423)

  • 21. Biomarker-guided sequential targeted therapies to overcome therapy resistance in rapidly evolving highly aggressive mammary tumors.
    Sahin O; Wang Q; Brady SW; Ellis K; Wang H; Chang CC; Zhang Q; Priya P; Zhu R; Wong ST; Landis MD; Muller WJ; Esteva FJ; Chang J; Yu D
    Cell Res; 2014 May; 24(5):542-59. PubMed ID: 24675532
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Concurrent biological targeting therapy of squamous cell carcinoma of the esophagus with cetuximab and trastuzumab.
    Yamazaki M; Yamashita Y; Kubo N; Yashiro M; Ohira M; Ako E; Tanaka H; Muguruma K; Sawada T; Hirakawa K
    Oncol Rep; 2012 Jul; 28(1):49-54. PubMed ID: 22562413
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hedgehog signaling is a novel therapeutic target in tamoxifen-resistant breast cancer aberrantly activated by PI3K/AKT pathway.
    Ramaswamy B; Lu Y; Teng KY; Nuovo G; Li X; Shapiro CL; Majumder S
    Cancer Res; 2012 Oct; 72(19):5048-59. PubMed ID: 22875023
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Regulation of ERBB2 receptor by t-DARPP mediates trastuzumab resistance in human esophageal adenocarcinoma.
    Hong J; Katsha A; Lu P; Shyr Y; Belkhiri A; El-Rifai W
    Cancer Res; 2012 Sep; 72(17):4504-14. PubMed ID: 22745369
    [TBL] [Abstract][Full Text] [Related]  

  • 25. GLI1 promotes cancer stemness through intracellular signaling pathway PI3K/Akt/NFκB in colorectal adenocarcinoma.
    Yang Z; Zhang C; Qi W; Cui Y; Xuan Y
    Exp Cell Res; 2018 Dec; 373(1-2):145-154. PubMed ID: 30321514
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Gli as a novel therapeutic target in malignant pleural mesothelioma.
    Li H; Lui N; Cheng T; Tseng HH; Yue D; Giroux-Leprieur E; Do HT; Sheng Q; Jin JQ; Luh TW; Jablons DM; He B
    PLoS One; 2013; 8(3):e57346. PubMed ID: 23483902
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A preclinical evaluation of the PI3K alpha/delta dominant inhibitor BAY 80-6946 in HER2-positive breast cancer models with acquired resistance to the HER2-targeted therapies trastuzumab and lapatinib.
    Elster N; Cremona M; Morgan C; Toomey S; Carr A; O'Grady A; Hennessy BT; Eustace AJ
    Breast Cancer Res Treat; 2015 Jan; 149(2):373-83. PubMed ID: 25528022
    [TBL] [Abstract][Full Text] [Related]  

  • 28. IL-22 induced cell proliferation is regulated by PI3K/Akt/mTOR signaling cascade.
    Mitra A; Raychaudhuri SK; Raychaudhuri SP
    Cytokine; 2012 Oct; 60(1):38-42. PubMed ID: 22840496
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Non-canonical GLI1/2 activation by PI3K/AKT signaling in renal cell carcinoma: A novel potential therapeutic target.
    Zhou J; Zhu G; Huang J; Li L; Du Y; Gao Y; Wu D; Wang X; Hsieh JT; He D; Wu K
    Cancer Lett; 2016 Jan; 370(2):313-23. PubMed ID: 26577809
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Synthetic lethal interaction between PI3K/Akt/mTOR and Ras/MEK/ERK pathway inhibition in rhabdomyosarcoma.
    Guenther MK; Graab U; Fulda S
    Cancer Lett; 2013 Sep; 337(2):200-9. PubMed ID: 23684925
    [TBL] [Abstract][Full Text] [Related]  

  • 31. GLI inhibitor GANT-61 diminishes embryonal and alveolar rhabdomyosarcoma growth by inhibiting Shh/AKT-mTOR axis.
    Srivastava RK; Kaylani SZ; Edrees N; Li C; Talwelkar SS; Xu J; Palle K; Pressey JG; Athar M
    Oncotarget; 2014 Dec; 5(23):12151-65. PubMed ID: 25432075
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficient elimination of pancreatic cancer stem cells by hedgehog/GLI inhibitor GANT61 in combination with mTOR inhibition.
    Miyazaki Y; Matsubara S; Ding Q; Tsukasa K; Yoshimitsu M; Kosai K; Takao S
    Mol Cancer; 2016 Jun; 15(1):49. PubMed ID: 27349387
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The PI3 kinase/mTOR blocker NVP-BEZ235 overrides resistance against irreversible ErbB inhibitors in breast cancer cells.
    Brünner-Kubath C; Shabbir W; Saferding V; Wagner R; Singer CF; Valent P; Berger W; Marian B; Zielinski CC; Grusch M; Grunt TW
    Breast Cancer Res Treat; 2011 Sep; 129(2):387-400. PubMed ID: 21046231
    [TBL] [Abstract][Full Text] [Related]  

  • 34. PI3K inhibition overcomes trastuzumab resistance: blockade of ErbB2/ErbB3 is not always enough.
    Hynes NE; Dey JH
    Cancer Cell; 2009 May; 15(5):353-5. PubMed ID: 19411062
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Oncogenic KRAS activates hedgehog signaling pathway in pancreatic cancer cells.
    Ji Z; Mei FC; Xie J; Cheng X
    J Biol Chem; 2007 May; 282(19):14048-55. PubMed ID: 17353198
    [TBL] [Abstract][Full Text] [Related]  

  • 36. mTOR, p70S6K, AKT, and ERK1/2 levels predict sensitivity to mTOR and PI3K/mTOR inhibitors in human bronchial carcinoids.
    Gagliano T; Bellio M; Gentilin E; Molè D; Tagliati F; Schiavon M; Cavallesco NG; Andriolo LG; Ambrosio MR; Rea F; Degli Uberti E; Zatelli MC
    Endocr Relat Cancer; 2013 Aug; 20(4):463-75. PubMed ID: 23653462
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dual PI3K/mTOR inhibitor NVP-BEZ235-induced apoptosis of hepatocellular carcinoma cell lines is enhanced by inhibitors of autophagy.
    Chang Z; Shi G; Jin J; Guo H; Guo X; Luo F; Song Y; Jia X
    Int J Mol Med; 2013 Jun; 31(6):1449-56. PubMed ID: 23588698
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Id-1 activation of PI3K/Akt/NFkappaB signaling pathway and its significance in promoting survival of esophageal cancer cells.
    Li B; Cheung PY; Wang X; Tsao SW; Ling MT; Wong YC; Cheung AL
    Carcinogenesis; 2007 Nov; 28(11):2313-20. PubMed ID: 17638919
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Expression of Hedgehog Pathway Mediator GLI Represents a Negative Prognostic Marker in Human Acute Myeloid Leukemia and Its Inhibition Exerts Antileukemic Effects.
    Wellbrock J; Latuske E; Köhler J; Wagner K; Stamm H; Vettorazzi E; Vohwinkel G; Klokow M; Uibeleisen R; Ehm P; Riecken K; Loges S; Thol F; Schubert C; Amling M; Jücker M; Bokemeyer C; Heuser M; Krauter J; Fiedler W
    Clin Cancer Res; 2015 May; 21(10):2388-98. PubMed ID: 25745035
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dual inhibition of PI3K and mTOR mitigates compensatory AKT activation and improves tamoxifen response in breast cancer.
    Chen X; Zhao M; Hao M; Sun X; Wang J; Mao Y; Zu L; Liu J; Shen Y; Wang J; Shen K
    Mol Cancer Res; 2013 Oct; 11(10):1269-78. PubMed ID: 23814023
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.